Poolbeg announces strategic expansion of POLB 001 into oncology

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications

Key Highlights

·      Newly filed patent application to protect use of POLB 001 for new oncology indication

·      Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies

·      Patent application covers a method of use of all p38 inhibitors during CAR T cell therapy

·      Progressing towards trial initiation in CAR T cell patients in 2024


16 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces the strategic expansion of POLB 001 into oncology. While investigating the role of cytokine release syndrome (“CRS”) in severe influenza, Poolbeg discovered data specific to the overt immune response in CAR T cell patients that suggest POLB 001 as a potential treatment option for this severe complication. The Company has submitted a patent application for the use of POLB 001 in addressing the impact of CRS in CAR T cell patients.

Read more…